Berberine in the Treatment of Diabetes Mellitus: A Review

Author(s): Aleksandra Baska*, Kamil Leis, Przemysław Gałązka

Journal Name: Endocrine, Metabolic & Immune Disorders - Drug Targets
Formerly Current Drug Targets - Immune, Endocrine & Metabolic Disorders

Volume 21 , Issue 8 , 2021


Become EABM
Become Reviewer
Call for Editor

Abstract:

Berberine is an alkaloid found in plants. It has neuroprotective, anti-inflammatory and hypolipidemic activities. The research proves that it also strongly impacts carbohydrate metabolism. The compound also protects pancreatic β-cells and increases sensitivity to insulin in peripheral tissues via the induction of GLUT-1, GLUT-4 and insulin type 1 (Ins-1) receptors activity. It also stimulates glycolysis and leads to a decrease in insulin resistance by macrophages polarization, lipolytic processes induction and energy expenditure enhancement (by reducing body mass and limiting insulin resistance caused by obesity). In liver berberine inhibits FOX01, SREBP1 and ChREBP pathways, and HNF-4α (hepatocyte nuclear factor 4 alpha) mRNA that hinder gluconeogenesis processes. In the intestines it blocks α-glucosidase contributing to glucose absorption decrease. Its interference in intestinal flora reduces levels of monosaccharides and suppresses diabetes mellitus complications development.

Keywords: Berberine, alkaloid, diabetes mellitus, metabolism, nutrition, review.

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 21
ISSUE: 8
Year: 2021
Page: [1379 - 1386]
Pages: 8
DOI: 10.2174/1568026620666201022144405
Price: $95

Article Metrics

PDF: 287